Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omission of CTV in LS-SCLC
NCT07008716Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial in small cell lung cancer (SCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Local progression free survival at 3 years and Severe toxicity free survival at 3 years. Started Jun 2025; status: recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07008716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008716.